PPM1D Modulates Hematopoietic Cell Fitness and Response to DNA Damage and Is a Therapeutic Target in Myeloid Malignancy

Scientists showed that while Ppm1d activation confered cellular resistance to cytotoxic therapy, it did so to a lesser degree than p53 loss, informing the clonal competition phenotypes often observed in human studies. Notably, loss of Ppm1d sensitized leukemias to cytotoxic therapies in vitro and in vivo, even in the absence of a Ppm1d mutation.